Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight

prnewswire.com
LIVN LivoNova's VNS System is mentioned as a marketed therapy for drug-resistant epilepsy. While part of the competitive landscape, the article does not provide specific details on its recent performance or future outlook, suggesting a neutral sentiment. PTC PTC Therapeutics is mentioned in the context of drug-resistant epilepsy pipeline insights. However, the article lacks specific details on their contributions or market outlook, leading to a neutral sentiment. UCB UCB is mentioned multiple times in relation to epilepsy markets. While a significant player, the article does not provide specific forward-looking statements or performance indicators for UCB in the drug-resistant epilepsy segment, resulting in a neutral sentiment. XENE Xenon Pharmaceuticals is mentioned in the context of partial epilepsy and epilepsy markets. The article does not provide specific details regarding their drug-resistant epilepsy pipeline or market performance, leading to a neutral sentiment. AQST Aquestive Therapeutics is listed as a key epilepsy company. However, the article lacks specific details on their involvement or performance in the drug-resistant epilepsy market, resulting in a neutral sentiment. TAK Takeda is mentioned as a key epilepsy company. The article does not provide specific information about their advancements or market position within the drug-resistant epilepsy segment, hence the sentiment is neutral. BHVN Biohaven Pharmaceuticals is listed as a key epilepsy company. The article does not provide specific information about their drug-resistant epilepsy pipeline or market performance, hence the sentiment is neutral. KNOP Knopp Biosciences is mentioned as a key epilepsy company. The article lacks specific details on their drug-resistant epilepsy pipeline or market strategy, resulting in a neutral sentiment. VRTX Vertex Pharmaceuticals is mentioned as a key company in the partial epilepsy market. The article does not provide specific details regarding their drug-resistant epilepsy pipeline or market performance, hence the sentiment is neutral. SUPN Supernus Pharmaceuticals is listed as a key company in the partial epilepsy market. The article does not provide specific details on their drug-resistant epilepsy pipeline or market strategy, resulting in a neutral sentiment. GSK GlaxoSmithKline is mentioned as a key company in the chronic focal epilepsy market. The article does not provide specific details about their drug-resistant epilepsy pipeline or market outlook, leading to a neutral sentiment. SNY Sanofi is listed as a key company in the chronic focal epilepsy market. The article lacks specific details on their drug-resistant epilepsy pipeline or market strategy, resulting in a neutral sentiment. MD Medtronic is mentioned as a key company in the chronic focal epilepsy market. The article does not provide specific details regarding their drug-resistant epilepsy pipeline or market performance, hence the sentiment is neutral.

DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness, and supportive regulations across the 7MM. Additionally, the launch of emerging drugs such as will further propel the market growth.

LAS VEGAS, Feb. 24, 2026 /PRNewswire/ -- Recently published Drug-Resistant Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, drug-resistant epilepsy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Drug-Resistant Epilepsy Market Summary

Discover what is the global market size for drug-resistant epilepsy and projected forecasts by year 2036 @ https://www.delveinsight.com/sample-request/drug-resistant-epilepsy-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Drug-Resistant Epilepsy Market

Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, commented that advancing the drug-resistant epilepsy pipeline reflects growing recognition of DRE as a biologically distinct, high-unmet-need condition and supports cautious optimism for durable, disease-modifying therapies and an increasingly differentiated epilepsy market.

Drug-Resistant Epilepsy Market Analysis

Drug-Resistant Epilepsy Competitive Landscape

Some of the drug-resistant epilepsy therapies and devices in the pipeline include NRTX-1001 (Neurona Therapeutics), IAMA-6 (IAMA Therapeutics), BM-101 (Bright Minds Bio), and others.

Neurona Therapeutics' NRTX-1001 is produced from human stem cells that are transformed into interneurons resembling those naturally present in the brain. These cells release GABA, a major neurotransmitter thought to reduce seizure activity by dampening overactive neural circuits.

IAMA Therapeutics' IAMA-6 is an orally delivered small-molecule therapy designed to selectively block NKCC1 and help rebalance neuronal excitability. Increased NKCC1 activity is associated with several disease states, underscoring the therapeutic potential of targeting this transporter in drug-resistant epilepsy and other neurological conditions.

Bright Minds Bio's BMB-101 is a first-in-class, structure-guided agonist of the 5-HT2C receptor that favors Gq-protein signaling. It is purposefully designed for chronic neurological diseases in which tolerance and treatment resistance limit long-term outcomes. By activating the Gq pathway while avoiding β-arrestin signaling, BMB-101 aims to minimize receptor desensitization and slow tolerance development. This pathway-selective approach within a well-validated receptor system supports a distinct anti-seizure mechanism intended to provide durable seizure control for patients with difficult-to-treat epilepsy.

The anticipated launch of these emerging therapies are poised to transform the drug-resistant epilepsy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the drug-resistant epilepsy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about what therapies are driving market growth for drug-resistant epilepsy @ Drug-Resistant Epilepsy Drugs Market

Recent Developments in the Drug-Resistant Epilepsy Market

What is Drug-Resistant Epilepsy?

Drug-resistant epilepsy (DRE), also called refractory or intractable epilepsy, is a condition in which a person's seizures continue despite trying at least two appropriately chosen and well-tolerated anti-seizure medications, either alone or in combination. In DRE, the brain's abnormal electrical activity does not respond adequately to standard drug therapy, leading to ongoing seizures that can significantly affect daily life, safety, and overall health. Because medications are not sufficient, people with drug-resistant epilepsy often require specialized evaluation to explore other treatment options such as epilepsy surgery, neurostimulation devices, or dietary therapies.

Drug-Resistant Epilepsy Epidemiology Segmentation

The drug-resistant epilepsy epidemiology section provides insights into the historical and current drug-resistant epilepsy patient pool and forecasted trends for the leading markets. DRE tends to be more common in adults than in children. While around 7% to 20% of kids with epilepsy struggle to control their seizures with medication, that number jumps to between 30% and 40% in adults.

The drug-resistant epilepsy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Drug-Resistant Epilepsy Market Forecast Report Metrics

Details

Study Period

2022–2036

Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Drug-Resistant Epilepsy Epidemiology Segmentation

Age- specific Diagnosed Prevalent Cases of Epilepsy, Treatable Cases of Epilepsy, and DRE Cases

Key Drug-Resistant Epilepsy Companies

Neurona Therapeutics, IAMA Therapeutics, Bright Minds Bio, and others

Key Drug-Resistant Epilepsy Therapies

NRTX-1001, IAMA-6, BM-101, and others

Scope of the Drug-Resistant Epilepsy Market Report

Download the report to understand what are the unmet needs in treating drug-resistant epilepsy @ Drug-Resistant Epilepsy Market Forecast

Table of Contents

1

Drug-Resistant Epilepsy Market Key Insights

2

Drug-Resistant Epilepsy Market Report Introduction

3

DRE Market Overview at a Glance

3.1

Market Share (%) Distribution of DRE by Therapies in 2025

3.2

Market Share (%) Distribution of DRE by Therapies in 2036

4

Executive Summary

5

Epidemiology and Market Methodology

6

Key Events

7

Disease Background and Overview

7.1

Introduction

7.2

Signs and Symptoms

7.3

Causes

7.4

Potential Mechanisms of Anti-Seizure Drug (ASD) Resistance

7.5

Classification

7.6

Risk Factors

7.7

Pathophysiology of Epilepsy

7.8

Diagnosis

7.9

Treatment

8

Epidemiology and Patient Population

8.1

Key Findings

8.2

Assumptions and Rationale: The 7MM

8.3

Total DRE Cases in the 7MM

8.4

United States

8.4.1

Age- specific Diagnosed Prevalent cases of Epilepsy

8.4.2

Treatable Cases of Epilepsy

8.4.3

DRE Cases

8.5

EU4 and the UK

8.6

Japan

9

Drug-Resistant Epilepsy Patient Journey

10

Marketed Drug-Resistant Epilepsy Therapies

10.1

Key Cross Competition

10.2

VNS System: LivoNova

10.2.1

Product Description

10.2.2

Other Development Activities

10.2.3

Clinical Development

10.2.4

Clinical Trials Information

10.2.5

Safety and Efficacy

List to be continued in the report…

11

Emerging Drug-Resistant Epilepsy Therapies

11.1

Key Cross Competition

11.2

NRTX-1001: Neurona Therapeutics

11.2.1

Drug Description

11.2.2

Other Developmental Activities

11.2.3

Clinical Trials Information

11.2.4

Safety and Efficacy

11.2.5

Analysts' View

11.3

IAMA-6: IAMA Therapeutics

11.4

BM-101: Bright Minds Bio

List to be continued in the report…

12

Drug-Resistant Epilepsy Market: 7MM Analysis

12.1

Key Findings

12.2

Key Drug-Resistant Epilepsy Market Forecast Assumptions

12.3

Drug-Resistant Epilepsy Market Outlook

12.4

Attribute Analysis

12.5

Market Size of DRE in the 7MM

12.6

Total Market Size of DRE by Therapies in the 7MM

12.7

United States Drug-Resistant Epilepsy Market Size

12.7.1

Total Market Size of DRE

12.7.2

Market size of DRE by Therapies in the US

12.8

EU4 and the UK Drug-Resistant Epilepsy Market Size

12.9

Japan Drug-Resistant Epilepsy Market

13

Key Opinion Leaders' Views on Drug-Resistant Epilepsy

14

Drug-Resistant Epilepsy Market SWOT Analysis

15

Drug-Resistant Epilepsy Market Unmet Needs

16

Drug-Resistant Epilepsy Market Access and Reimbursement

16.1

The United States

16.2

In EU4 and the UK

16.3

Japan

17

Bibliography

18

Acronyms and Abbreviations

19

Drug-Resistant Epilepsy Market Report Methodology

Related Reports

Drug-Resistant Epilepsy Clinical Trial Analysis

Drug-Resistant Epilepsy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Drug-Resistant Epilepsy companies, including ES Therapeutics, PTC Therapeutics, Aadi Bioscience, MGC Pharma, UCB, Zogenix, and others.

Epilepsy Market

Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies, including Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.

Chronic Focal Epilepsy Market

Chronic Focal Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic focal epilepsy companies, including GlaxoSmithKline, Sanofi, UCB Pharma, Eisai, Medtronic, and others.

Partial Epilepsy Market

Partial Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key partial epilepsy companies, including Vertex Pharmaceuticals, Supernus Pharmaceuticals, Xenon Pharmaceuticals, UCB Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP